Consenso del Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL) para el manejo del Linfoma en estado de Pandemia   SARS CoV-2 / COVID 19

Ospina-Idárraga, Juan Alejandro; Martínez-Cordero, Humberto; Idrobo-Quintero, Henry; Ortiz-Alfaro, Conrad; Martínez-Correa, Lina María; García, Juan Esteban; Malpica, Luis; Castillo, Jorge J.; Torres, María Alejandra; Villela, Luís; Candelaria, Myrna; Glasenapp, Alana Von; Beltrán, Brady E; Paredes, Sally Rose; Castro, Denisse; Prates, Virginia; Fiad, Lorena; Di, Marcos; Riva, E.; Abello-Polo, Virginia; Choque, Juan Antonio; Peña, Camila; Rojas, Christine; Valvert-Gamboa, Fabiola

doi:10.35509/01239015.690

Cited by 4 publications

(7 citation statements)

References 158 publications

(162 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La literatura actual no muestra guías de recomendaciones basadas en evidencias científicas de alto nivel, ya que a causa del COVID-19, no se ha podido evaluar los desenlaces relevantes de los pacientes con cáncer durante el desarrollo de esta pandemia (7) . Se han identificado diferentes documentos de recomendación, nacionales e internacionales, que brindan una serie de recomendaciones acorde a la priorización, las cuales han servido para poder realizar un consenso para generar un orden de priorización teniendo en cuenta el desarrollo en el ámbito local (1,(8)(9)(10)(11)(12) .…”

Section: Resultsunclassified

“…• Se recomienda postergar el inicio de rituximab durante el ascenso de la curva de pandemia (fase 2 y 3) y luego incorporarlo de manera secuencial (10) .…”

Section: Linfomaunclassified

“…• Solo se recomienda trasplante autólogo de precursores en pacientes con linfomas con alto riesgo de recaída que termina esquemas de rescate con buena respuesta. Valorar adicionar un ciclo de quimioterapia antes del trasplante autólogo (10,31,32) .…”

Section: Linfomaunclassified

“…• El régimen R-DA-EPOCH se recomienda en pacientes con linfoma de Células B primario mediastinal y linfomas asociados a VIH. Los pacientes con doble/ triple hit podría recibir R-CHOP y luego trasplante autólogo de consolidación (10,32) .…”

Section: Linfomaunclassified

“…• Se recomienda que los pacientes con Linfoma B agresivo y con alto riesgo de recurrencia al SNC, deben recibir tratamiento de metotrexato endovenoso a altas dosis, como mínimo 2 cursos, después de los seis ciclos de quimioterapia (10,32) .…”

Section: Linfomaunclassified

See 4 more Smart Citations

Clinical recommendations for the management of cancer patients in the context of the COVID-19 pandemic

Leiva¹,

Beltrán²,

Alarcón³

et al. 2020

RFMH

View full text Add to dashboard Cite

show abstract

Section: Resultsunclassified

“…• Se recomienda postergar el inicio de rituximab durante el ascenso de la curva de pandemia (fase 2 y 3) y luego incorporarlo de manera secuencial (10) .…”

Section: Linfomaunclassified

See 3 more Smart Citations

Clinical recommendations for the management of cancer patients in the context of the COVID-19 pandemic

Leiva¹,

Beltrán²,

Alarcón³

et al. 2020

RFMH

View full text Add to dashboard Cite

show abstract

Manejo de neoplasias oncohematológicas en el contexto de la pandemia de COVID-19: recomendación de expertos

et al. 2021

Self Cite

View full text Add to dashboard Cite

La pandemia COVID-19 originado por el Coronavirus 2, agente causal del síndrome respiratorio agudo severo (SARS-CoV-2) ha desencadenado una crisis de salud pública a nivel global. Muchos reportes indican resultados desalentadores en pacientes con cáncer respecto a la población general. Por ello, los expertos en el manejo de neoplasias oncohematológicas del Instituto Nacional de Enfermedades Neoplásicas, hospitales nacionales y una clínica privada de Lima Metropolitana han desarrollado recomendaciones obtenidas por consenso para continuar con el manejo de pacientes con neoplasias oncohematológicas en forma segura ante la coyuntura de pandemia.

show abstract

Oncological Care During First Peruvian National Emergency COVID-19 Pandemic: A Multicentric Descriptive Study

Valdiviezo¹,

Alcarraz²,

Castro³

et al. 2022

CMAR

View full text Add to dashboard Cite

Purpose The aim of this study is to evaluate the oncological care during the first state of national emergency due to the COVID-19 pandemic in several public cancer hospitals in Peru. Materials and Methods A multicentric cross-sectional descriptive study was conducted by interviewing adult cancer patients diagnosed and treated between January 2019 and February 2020 from 18 hospitals. This study was carried out in September 2020, the last month of the first state of national emergency. Demographic and clinical characteristics were evaluated, including COVID-19 status and cancer treatment features. Results A total of 1472 patients were included; the median age was 55 years (range 19–97). Most patients (85.8%, n = 1263) had solid neoplasia, 13.5% (n = 198) hematologic neoplasia, and 0.7% (n = 11) others. SARS-CoV-2 infection was confirmed in 8.6% (n = 126), 1.2% (n = 18) were probable, 1.6% (n = 24) suspected, and 88.6% (n = 1304) negative cases. Overall, 51.6% of patients (n = 759) had cancer treatment delays, 42.5% (n = 626) changed treatment delivery (endovenous to oral systemic therapy), and 12.6% (n = 185) of cases cancer therapy was discontinued. In total, 10.3% (n = 117) of patients whose disease was controlled or in remission, experienced progression of disease during the state of emergency. A total of 6.7% (n = 98) of patients died, of whom 73.5% (n = 72) died from disease progression; 18.4% (n = 18) from SARS-CoV-2 infection and 8.1% (n = 8) from undetermined causes. Patients with hematological malignancies [hazard ratio (HR): 5.11 (95% confidence interval (CI): 1.99–13.07)] and no response to therapy before the onset of the pandemic [5.01 (1.44–17.42)] had an increased risk of death among COVID-19 infected individuals, whereas advanced clinical stage [5.09 (2.37–10.95)] and discontinuation of treatment [3.66 (1.97–6.78)] were risk factors among non-COVID-19 patients. Conclusion Our study suggests that the COVID-19 pandemic has an adverse impact on the outcomes of Peruvian cancer patients. In our cohort, cancer mortality was higher than COVID-19 disease mortality.

show abstract

Consenso del Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL) para el manejo del Linfoma en estado de Pandemia SARS CoV-2 / COVID 19

Cited by 4 publications

References 158 publications

Clinical recommendations for the management of cancer patients in the context of the COVID-19 pandemic

Clinical recommendations for the management of cancer patients in the context of the COVID-19 pandemic

Manejo de neoplasias oncohematológicas en el contexto de la pandemia de COVID-19: recomendación de expertos

Oncological Care During First Peruvian National Emergency COVID-19 Pandemic: A Multicentric Descriptive Study

Contact Info

Product

Resources

About